ArticleArthritis care & research2025
Prevalence and Clinical Characteristics of Vasculitis in the Alaska Native and American Indian Peoples of Alaska.
Article in Arthritis care & research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rheumatic disease in Canada's Northwest Territories: baseline review and comparative insights.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveOur objective was to determine the prevalence and clinical characteristics of vasculitis in Alaska Native and American Indian (AN/AI) peoples of Alaska.
methodsWe queried the electronic health records of participating tribal health organizations within the Alaska Tribal Health System (ATHS) to identify adults with diagnostic codes related to vasculitis. Medical record abstraction was performed for all adults with potential vasculitis to confirm fulfillment of inclusion criteria, subtype, and clinical characteristics. The denominator for prevalence was the 2019 ATHS user population ≥ 18 (except giant cell arteritis [GCA], defined for persons ≥ 50).
resultsThe age-adjusted prevalence per 1,000,000 AN/AI adults was 752 (95% confidence interval [CI] 581-959) for all vasculitis, with systemic vasculitis being the most common at 518 (95% CI 379-695). The most prevalent types of systemic vasculitis were antineutrophil cytoplasmic antibody-associated vasculitis (AAV) at 340 per million adults (95% CI 230-488) and GCA at 28 per 100,000 ≥ 50 (95% CI 12-56). The most prevalent subtype of AAV was granulomatosis with polyangiitis (GPA) at 244 per million adults (95% CI 148-380). AAV was diagnosed at a mean age of 54.2 years (SD 17), often with high markers of inflammation and renal involvement. GCA was diagnosed at a mean age of 69.6 years (SD 9.2).
conclusionThe prevalence of AAV (especially GPA) in AN/AI peoples is high. GCA prevalence is lower than White populations, but higher than many other populations. AN/AI peoples with AAV and GCA may present at younger ages with more severe disease than other populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.